A digital therapeutics programme for people with psoriasis has gone live in Spain, Italy and the United Kingdom. The Claro programme aims to provide personalised digital therapeutics, coaching and care to support the mental well being and quality of life for people with psoriasis.

Claro is the result of a collaboration between digital therapeutics AI company Happify Health and Spanish biopharmaceutical company Almirall SA.

Psoriasis is one of the world’s most prevalent skin diseases, affecting about 60 million people worldwide. A 2019 study in Maedica, a Journal of Clinical Medicine, establishes a clear link between skin psychology and quality of life for people with psoriasis. It is estimated that 20% to 30% of people, globally, with moderate to severe psoriasis also suffer from mental health issues, like anxiety and depression1. Approximately 80% of those affected with psoriasis have mild to moderate symptoms, with direct healthcare costs for treatment of psoriasis exceeding $65 billion annually.

“At Almirall, we are proud to offer psoriasis patients a wide range of medicines that cover the whole spectrum of the disease, from mild to severe. Claro helps us to fulfil our commitment to people living with psoriasis, providing them with an enhanced solution addressed to their wellbeing, so they can get their lives back,” said Dr. Volker Koscielny, MD, Chief Medical Officer of Almirall.

“Psoriasis is a significant burden in the daily life of 71% of people who suffer from it, according to the National Psoriasis Foundation in the UK,” said Theo Ahadome, Senior Vice President of Commercialisation at Happify Health. “We are very pleased with the level of engagement we are seeing so far among Claro users, and this partnership gives us the opportunity to study how effective digital programmes are at keeping psoriasis patients engaged during treatment for psoriasis and improving their quality of life.”